Chemoinformaics analysis of 9,10,13-Trihydroxy-11-octadecenoic acid
| Molecular Weight | 330.465 | nRot | 15 |
| Heavy Atom Molecular Weight | 296.193 | nRig | 2 |
| Exact Molecular Weight | 330.241 | nRing | 0 |
| Solubility: LogS | -3.011 | nHRing | 0 |
| Solubility: LogP | 3.099 | No. of Aliphatic Rings | 0 |
| Acid Count | 1 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 57 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 23 | No. of Aromatic Carbocycles | 0 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 34 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 18 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 5 | No. of Arom Bond | 0 |
| nHA | 4 | APOL | 56.741 |
| nHD | 4 | BPOL | 34.977 |
| QED | 0.273 |
| Synth | 3.415 |
| Natural Product Likeliness | 1.679 |
| NR-PPAR-gamma | 0.914 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.008 |
| HIA | 0.9 |
| CACO-2 | -5.362 |
| MDCK | 0.0000519 |
| BBB | 0.652 |
| PPB | 0.936064 |
| VDSS | 0.522 |
| FU | 0.0414876 |
| CYP1A2-inh | 0.07 |
| CYP1A2-sub | 0.231 |
| CYP2c19-inh | 0.012 |
| CYP2c19-sub | 0.069 |
| CYP2c9-inh | 0.021 |
| CYP2c9-sub | 0.989 |
| CYP2d6-inh | 0.005 |
| CYP2d6-sub | 0.092 |
| CYP3a4-inh | 0.008 |
| CYP3a4-sub | 0.015 |
| CL | 4.628 |
| T12 | 0.856 |
| hERG | 0.016 |
| Ames | 0.015 |
| ROA | 0.024 |
| SkinSen | 0.235 |
| Carcinogencity | 0.024 |
| EI | 0.04 |
| Respiratory | 0.074 |
| NR-Aromatase | 0.024 |
| Antiviral | Yes |
| Prediction | 0.734897 |